Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model

Gastón Perman1,2*, Emiliano Rossi1, Gabriel D Waisman3, Cristina Agüero4, Claudio D González5, Carlos L Pallordet6, Silvana Figar2, Fernán González7, JoAnn Canning8 and Enrique R Soriano8

Abstract

Background: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer.

Methods: We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer’s perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.

Results: The ICER for the base-case of the “Hypertension Programme” versus the “Usual care” approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.

Discussion: Results showed that “Hypertension Programme” had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.

Conclusions: The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.

Background

Over the last three decades, clinical research has shown that effective hypertension treatment lowers cardiovascular events and related deaths [1-12]. In spite of this medical benefit there is increasing worldwide concern about the economic burden of hypertension and associated cardiovascular outcomes [13].
analysis; lack of hard outcome measures; exclusive use of secondary databases; and/or deficiencies in sensitivity analysis.

Most economic evaluations in hypertension have focused on the comparison of two drug treatments. The major problem with these evaluations is that they offer little direction to decision makers related to what kind of health services to provide. They address questions limited to a few treatment options for only one aspect -pharmacologic- of hypertension treatment. Moreover, analysis has been primarily based on clinical trials that analyze efficacy in ideal settings not real-life effectiveness.

In year 2000, we started a multidisciplinary antihypertensive programme for elderly patients at Hospital Italiano de Buenos Aires in Argentina. Its effectiveness was demonstrated elsewhere [14]. In this study we evaluate if our hypertension management programme is cost-effective compared to usual care from the perspective of a third-party payer.

Methods
Description of different treatment options
The effectiveness of a hypertension management programme in middle-class patients 65 years or older was determined by a quasi-experimental, individual-based study [14] with a control group. This study had been previously approved by an Ethics Committee. We compared the intervention -“Hypertension Programme”- against “Usual care” -the control group- using a pragmatic design (i.e. the study was designed to capture the effects of interventions as they were usually performed, avoiding artificial changes due to research protocol).

“Usual care” consisted of attention by primary care physicians (PCP). Visits to the PCP could be on a regular basis or whenever the patient asked for an appointment. There were no restrictions regarding studies, pharmacological treatments or specialty consultations -cardiologists, neurologists, etc., if the PCP agreed with them.

The new “Hypertension Programme” consisted of usual care described above plus: personal and telephone contact with patients by medical students; support with non-pharmacological treatment such as diet and physical activity; educational material and optional workshops focused on patient empowerment and self-efficacy; information recorded on an electronic health record that served as a link among health care workers.

Differences in systolic blood pressure (SBP) level and in percentage of well-controlled (< 140/90 mm Hg) patients between groups were measured at baseline and after 12 months of follow-up. Data were assessed by intention-to-treat analysis. Two hundred and fifty patients were evaluated in each group. There were no baseline differences between intervention and usual care groups besides age (73 vs. 72 years, respectively; p < 0.001; see Additional file 1, appendix). At baseline, mean blood pressure (systolic/diastolic) in mm Hg (SD) was 138(20)/75(11) vs. 135(19)/75(11); and percentage of well-controlled patients was 56.4% vs. 60.4%, respectively. At the end of the study period, the difference of mean change in systolic blood pressure between groups was 7.1 mm Hg (95% confidence interval, 4-10 mm Hg). Sixty-seven percent of patients in the intervention group were well-controlled, versus 51% of patients in the control group (p < 0.001). With these improved results the program was implemented in the whole population of hypertensive patients in the HMO. We used this information to build our model.

Model construction
Even though we had patient-level data to perform a cost-effectiveness analysis, we decided to build a theoretical model that considered these data because we could not track long-term costs and/or clinical outcomes in the original study groups (after the end of the study, the intervention was implemented in the whole population).

The theoretical model built considered two possible treatment options: “Hypertension Programme” or “Usual Care”. We used a Markov model to allow for repeated cardiovascular events. Each cycle lasted 1 year. Costs and outcomes were tracked through-out patient’s lifetime. Even though this life-time perspective might be controversial, we chose to not exclude very old patients because of recent evidence of beneficial effects of hypertension treatment in this age group [12]. Nevertheless, we also explored the cost-effectiveness of the model considering different follow-up times.

Independently of the treatment option chosen, patients could follow one of three different paths in each 1-year cycle, based on their transition probabilities (figure 1): a) Continue in the same health state without suffering any event; b) Have an acute cardiovascular event (acute myocardial infarction -AMI-, unstable angina -UA-, ischaemic stroke, haemorrhagic stroke, transient ischaemic attack -TIA-, heart failure -HF- and peripheral artery disease -PAD); or c) Die from causes other than cardiovascular disease. Patients who suffered a cardiovascular event could have acute hospital attention or not. All patients suffering an acute event could die during that year (cardiovascular death) or survive (at least for that year).

Transition probabilities depended on age and the general cardiovascular risk equation in the Framingham cohort study [25]. Because every patient had at least 65 years and hypertension at the start of the model, only two categories were included: intermediate and high risk (no patients with low risk). Irrespective of their basal risk, patients who survived after a cardiovascular event started
a new cycle in the high risk group. Every patient that completed each cycle in any state other than death received 1 year of life gained (LYG). Yearly costs according to the treatment group were also computed. If a patient had suffered a cardiovascular event in that year, hospital expenditures were charged only for those who received hospital attention.

**Assumptions**

Given that this model tried to capture a real-life scenario, we decided to include the probability of receiving hospital attention or not during an acute event. This is because of the relatively high proportion of patients with asymptomatic or atypical symptoms of cardiovascular events and/or sudden death. Patients assisted would have higher costs (related to hospital attention) and better survival outcome. These assumptions were the same for both groups (programme and usual care) because we considered that all hospitalized patients should have the same quality of health care in acute cardiovascular events.

**Sources of cost data**

We conducted a micro-costing analysis of all resources involved in running this program (see table 1). Total cost per item was the unit cost times the quantity used. Capital costs were calculated as equivalent annual costs for a 5-year period using a 5% discount rate. We calculated all costs in 2006 Argentinean Pesos and adjusted them to 2010 values using the average consumer price index of different provinces from Argentina [26-31]. We report values in International Dollars using the purchasing power parity conversion rate suggested by the International Monetary Fund [32].

Regarding hospital costs for complications we could not use data from the same cohort studied in the original trial because of time frame restrictions and the subsequent implementation of the intervention in the whole
## Table 1 Costs of the Hypertension Programme and Usual Care in 2010 International Dollars

| Concept                  | Hypertension Programme | Usual care |
|--------------------------|------------------------|------------|
|                          | Unit cost | Quantity | Annual cost | Unit cost | Quantity | Annual cost |
| Hypertension programme   |            |          |            |            |          |            |
| Labour                   |            |          |            |            |          |            |
| Physicians               | 15.73     | 3,168.00 | 49,820.80   | NA         | NA       | NA         |
| Fellows                  | 10.27     | 4,752.00 | 48,808.07   | NA         | NA       | NA         |
| Monitors                 | 5.29      | 15,744.00 | 83,272.20  | NA         | NA       | NA         |
| Education coordinator    | 24.22     | 204.00   | 4,940.97    | NA         | NA       | NA         |
| Educational workshops    | 20.76     | 564.03   | 11,708.14   | NA         | NA       | NA         |
| Secretary                | 6.60      | 528.00   | 3,485.35    | NA         | NA       | NA         |
| Nurse                    | 7.93      | 13,305.60 | 105,507.51 | NA         | NA       | NA         |
| Epidemiologist           | 14.16     | 120.00   | 1,698.83    | NA         | NA       | NA         |
| Labour subtotal          | 309,241.87 |          |            | NA         |          |            |
| Labour subtotal per patient | 10.31   |          |            | NA         |          |            |
| Capital                  |            |          |            |            |          |            |
| Coordinator's furnishings| 2,901.14  | 1.00     | 638.17      | NA         | NA       | NA         |
| Offices' furnishings     | 2,238.88  | 1.00     | 492.49      | NA         | NA       | NA         |
| Sphygmomanometer         | 90.50     | 7.00     | 139.36      | NA         | NA       | NA         |
| Coordinator's computers  | 1,703.98  | 5.00     | 1,874.16    | NA         | NA       | NA         |
| Offices' computers       | 1,703.98  | 4.20     | 1,574.29    | NA         | NA       | NA         |
| Capital costs subtotal   | 4,718.48  |          |            | NA         |          |            |
| Capital cost sub per patient | 0.16    |          |            | NA         |          |            |
| Land                     |            |          |            |            |          |            |
| Administrative office    | 112.09    | 7.50     | 10,088.39   | NA         | NA       | NA         |
| Medical office           | 112.09    | 7.50     | 10,088.39   | NA         | NA       | NA         |
| Support office           | 32.38     | 31.50    | 12,240.58   | NA         | NA       | NA         |
| Workshop space           | 16.61     | 564.03   | 9,366.51    | NA         | NA       | NA         |
| Land subtotal            | 41,783.86 |          |            | NA         |          |            |
| Land subtotal per patient | 1.39    |          |            | NA         |          |            |
| Resources                |            |          |            |            |          |            |
| Telephone                |            |          |            |            |          |            |
| Effective call           | 0.12      | 7,959.96 | 971.57      | NA         | NA       | NA         |
| Ineffective call (non-response) | 0.04 | 7,280.04 | 296.19      | NA         | NA       | NA         |
| Telephone subtotal       | 1,267.76  |          |            | NA         |          |            |
| Telephone subtotal per patient | 0.04 |          |            | NA         |          |            |
| Brochures                |            |          |            |            |          |            |
| Brochures                | 1.07      | 10,000.00 | 10,711.13  | NA         | NA       | NA         |
| Brochures subtotal       | 10,711.13 |          |            | NA         |          |            |
| Brochures subtotal per patient | 0.36 |          |            | NA         |          |            |
| Surveillance software    |            |          |            |            |          |            |
| Licence                  | 4,151.60  |          |            | NA         | NA       | NA         |
| Hardware support         | 5,579.75  |          |            | NA         | NA       | NA         |
| Software maintenance     | 18.52     | 2,376.00 | 44,000.26   | NA         | NA       | NA         |
| Office                   | 112.09    | 36.00    | 4,035.36    | NA         | NA       | NA         |
| Software development     | 11,588.72 |          |            | NA         | NA       | NA         |
| Server                   | 3,397.26  |          |            | NA         | NA       | NA         |
| Computer                 | 374.83    |          |            | NA         | NA       | NA         |
| Software subtotal        | 73,127.78 |          |            | NA         |          |            |
| Software subtotal per patient | 2.44   |          |            | NA         |          |            |
| Programme total          | 440,850.89 |          |            | NA         |          |            |
| Programme subtotal per patient | 14.70 |          |            | NA         |          |            |
| Overhead costs           |            |          |            |            |          |            |
population (including the usual care group). Thus, we decided to build a specific case-mix. We included all hospital admittances from cardiovascular events (AMI, UA, ischaemic stroke, haemorrhagic stroke, TIA, HF and PAD, coded using SNOMED-CT [33] in adult affiliates from 01/01/2006 to 12/31/2006. We tracked down costs (micro-costing) for each episode and then calculated the mean hospital cost per cardiovascular event as the average of all episodes during that period. Because the distribution was skewed to the right (as most cost data), we used the lognormal transformation for sensitivity analysis (see table 2).

The discount rate used for the base-case was 5% for both costs and effectiveness, according to recommendations from the Panel on Cost-Effectiveness in Health and Medicine [34]. In the sensitivity analysis we considered up to a 12% discount rate according to suggestions from the World Bank for Latin America and Argentina [35].

Sources of events and outcomes data
Annual rates of cardiovascular events for intermediate and high risk patients were calculated from the general cardiovascular risk equations in the Framingham cohort study [25]. Cardiovascular risk reduction from decreased

| Table 1 Costs of the Hypertension Programme and Usual Care in 2010 International Dollars (Continued) |
|---------------------------------------------------------------|
| Overhead Subtotal (per patient) | 1.98 | 8.14 | 16.07 | 1.98 | 7.64 | 15.08 |
| Medical visits per patient  § | | | | | | |
| Primary care physician | 9.63 | 7.40 | 71.30 | 9.63 | 6.90 | 66.48 |
| Specialist | 9.63 | 0.74 | 7.13 | 9.63 | 0.74 | 7.13 |
| Emergency ambulance service | 1.45 | 12.00 | 17.44 | 1.45 | 12.00 | 17.44 |
| Medical visits subtotal | | | | | | |
| Consumption per patient | | | | | | |
| Drugs | | | | | | |
| Cost diagnostic/follow-up tests per year | 29.10 | Uniform (20.37; 37.83) |
| Number of medical visits | 7.68 | Lognormal (1.68; 0.89) |
| Hypertension programme | | | | | | |
| Cost drugs/year | 216.55 | Lognormal (4.59; 1.26) |
| Cost diagnostic/follow-up tests per year | 36.19 | Uniform (25.33; 47.04) |
| Cost programme | 14.66 | Uniform (10.26; 19.06) |
| Number of medical visits | 4.72 | Lognormal (1.16; 0.85) |
| Annual Total (per patient) | 361.81 | 295.70 |

# Labour: cost/hour; Capital, Brochures and Software: cost per item; Land: cost per m2 per month or per hour rented.
* Telephone: cost per call; Overseas and Medical visit: cost per medical visit.
* Labour: number of hours/year; Capital, Brochures and Software: number of items; Land: total m2 or hours rented.
& Telephone: number of calls; Overseas and Medical visit: number of medical visits.
§ No co-payments were charged.
NA: Not applicable.

| Table 2 Variables for probabilistic sensitivity analysis: Costs in International Dollars for 2010 |
|---------------------------------------------------------------|
| Cost Variables | Base case | Distribution type | Distribution |
| Usual care | | | |
| Cost drugs/year | 206.43 | Lognormal | (4.36; 1.39) |
| Cost diagnostic/follow-up tests per year | 29.10 | Uniform | (20.37; 37.83) |
| Number of medical visits | 7.68 | Lognormal | (1.68; 0.89) |
| Hypertension programme | | | |
| Cost drugs/year | 216.55 | Lognormal | (4.59; 1.26) |
| Cost diagnostic/follow-up tests per year | 36.19 | Uniform | (25.33; 47.04) |
| Cost programme | 14.66 | Uniform | (10.26; 19.06) |
| Number of medical visits | 4.72 | Lognormal | (1.16; 0.85) |
| Common variables | | | |
| Overhead cost (per visit) | 1.98 | Uniform | (1.39; 2.57) |
| Cost per medical visit | 9.63 | Uniform | (6.74; 12.52) |
| Cost ambulance/year | 17.44 | Uniform | (12.21; 22.67) |
| Proportion of drugs coverage | 0.70 | Uniform | (0.40; 1.00) |
| Cost of cardiovascular event attention | 10041.65 | Lognormal | (8.24; 1.39) |
| Cost of diagnostic tests first year | 117.78 | Uniform | (82.44; 153.11) |
SBP was calculated as suggested by a meta-analysis of individual data for one million adults in 61 prospective studies [36] using differences in final SBP levels between “Usual Care” and “Hypertension Programme” groups. As many references on outcomes did not report risks by gender, we decided to use average results and to not discriminate between sexes in the model.

Since we wanted the model to capture the cost-effectiveness as in a real-life setting, we considered those potential patients that would not receive health care attention during an acute cardiovascular event. Thus, we calculated the proportion of patients not assisted taking into account sudden deaths -from cardiovascular origin- and asymptomatic events -e.g. asymptomatic AMI- or atypical presentations [37,38]. Mortality data from cardiovascular events were taken from the same populations used to fit other probabilities in the model [39-42].

Analysis
Since our aim was to inform decision makers from a third-party payer on the cost-effectiveness of these two approaches of hypertension treatment, we adopted this perspective to perform analyses. We did not have data from the original effectiveness study to also report results from a societal perspective. For the same reason, and budgetary constraints, we used life years gained (LYG) as an effectiveness measure and not quality-adjusted life years or other measure that considered health-state values. We did not extrapolate quality of life estimates from other populations due to clinically important differences in health states valuation in our region [43].

We calculated the incremental cost-effectiveness ratio between the different options using difference in costs in 2010 International Dollars divided by the difference in effectiveness in life years gained. All analyses were done with TreeAge Pro 2009 (TreeAge Software, Inc.).

We performed a one-way sensitivity analysis to explore the impact of each variable on results. A Tornado diagram analysis was used to assess the relative weight of each variable on overall uncertainty. We also explored variable uncertainty and the impact of simultaneous changes in variables included in the model with a probabilistic sensitivity analysis using Monte-Carlo simulations [44]. The model was run 100,000 times -iterations- taking different random samples of all variables used (except for discount rate). Tables 2 and 3 show variables used with its base case value and distribution.

Discount rate was considered a structural variable in the model. So, different analyses were performed with different discount rates, from 0 to 12%. A theoretical willingness to pay (WTP) threshold was set at Int$/LYG 45,000, corresponding to 3 times the gross domestic product (GDP) of Argentina in International Dollars for 2010 [32].

Due to its long-term perspective, model validation was performed according to Weinstein et al [45]. Face validity and verification were assessed during model construction, debugging and testing for internal consistency. Model results were consistent with observed data from mortality tables of populations were input data came from [46,47]. Corroboration was supported by the Markov model of the German hypertension treatment programme, although it had different health states and data sources [22]. Transparency and accreditation were sought through the publication of this research in an open access journal.

Results
The base case showed that the least costly but least effective strategy was “Usual care”. The “Hypertension Programme” had an incremental cost-effectiveness ratio (ICER) of 1,124 International Dollars per life-year gained (Int$/LYG). Results on total costs, effectiveness and incremental costs and effectiveness are shown in table 4.

The variable that accounted for the majority of the uncertainty was the discount rate. It explained 91.7% of the uncertainty in the model. The next one was the starting age, explaining an extra 7.3%. Including the proportion of patients in the cohort starting with high cardiovascular risk, these 3 variables accounted for 99.7% of the overall uncertainty.

We performed a probabilistic sensitivity analysis including all variables in the model, except for discount rate (see tables 2 and 3). The ICER scatterplot of “Hypertension Programme” versus “Usual care” is shown in figure 2 for a discount rate of 5%. None of the iterations showed less effectiveness. In 43% of them, “Hypertension Programme” was dominant. In addition, in 52% of cases the intervention had an ICER below a predefined WTP threshold of 45,000 Int$/LYG. Only 5% of iterations had an ICER above this threshold.

Being the discount rate the most sensitive variable, we ran the model and performed probabilistic sensitivity analyses for different values. Even at a discount rate of 12%, “Hypertension Programme” was dominant in 43% of cases. In 88.5% of times, the Programme was cost-effective.

The cost-effectiveness acceptability curve (CEAC) shows the probability of the “Hypertension Programme” being cost-effective compared to “No Treatment” in a wide range of willingness to pay thresholds (figure 3). Considering a discount rate of 5%, at a WTP of 15,000 Int$/LYG (corresponding to Argentina’s GDP for 2010), the “Hypertension Programme” had 82% probability of being cost-effective. At a WTP threshold of 45,000 Int$/LYG (3 times the GDP), the probability was 95%. See additional file 2: graphic S1 for CEAC for different discount rates.
Discussion

This study showed that this “Hypertension Programme” was more effective than “Usual care” at a relatively small incremental cost. The base case result of ICER 1,124 Int $/LYG is highly cost-effective in our local context. Moreover, in 43% of 100,000 iterations performed in the probabilistic sensitivity analysis, “Hypertension Programme” was dominant (more effective and less costly). Overall, in 95% of cases, the programme was cost-effective.

This is the first study to include all the following aspects: original (short term) effectiveness data based on a primary source; hard outcome measurements; a long-term analysis; and a probabilistic sensitivity analysis.

A literature review of four previous studies showed a combination of some methodological limitations in all of them: short-term analyses [21,24]; intermediate outcome measures [21,23]; a model based entirely on secondary sources [22]; or a biased sensitivity analysis [23].

In our model, the major determinant of uncertainty was the discount rate used. In general, benefits of hypertension treatments are seen several years after their start. As a result, the bigger the discount rate used, the lower the final benefit obtained. This is a common problem when considering cost-effectiveness of prevention programmes. Even though different discount rates produced different outputs, they would not significantly alter decision-making (see additional file 2: graphic S1).

Table 3 Variables for probabilistic sensitivity analysis: Outcomes

| Probability variables | Base-case | Distribution type | Distribution | Reference |
|-----------------------|-----------|-------------------|--------------|-----------|
| Reference population * | Risk event in medium risk 65-74 years | 0.0255 | Uniform | (0.0223; 0.0285) | [25,48] |
| Risk event in medium risk 75+ years | 0.0400 | Uniform | (0.0300; 0.0500) | [25,48] |
| Risk event high risk group 65-74 years | 0.0325 | Uniform | (0.0300; 0.0350) | [25,48] |
| Risk event in high risk group 75+ years | 0.2000 | Uniform | (0.1500; 0.2500) | [25,48] |
| Usual care group | Hazard ratio usual care group | 0.6150 | Normal | (0.6150; 0.0089) | [14,36] |
| Risk of event in middle risk group | a | | | |
| Risk of event in high risk group | b | | | |
| Hypertension programme group | Hazard ratio programme group | 0.5124 | Normal | (0.5124; 0.0131) | [14,36] |
| Risk of event in middle risk group | c | | | |
| Risk of event in high risk group | d | | | |
| Scenarios of HR in programme group | 0.5100 | Uniform | (0.4500-0.5700) | [14,36] |
| Common variables | Proportion initiate at medium risk | 0.7000 | Uniform | (0.0000;1.0000) | [14] |
| Starting age (years) | 65 | Uniform | (65-80) | |
| Risk of unrecognized event | 0.3670 | Uniform | (0.2500; 0.4000) | [38] |
| Risk of sudden death | 0.1000 | Uniform | (0.0600; 0.1400) | [37,30] |
| Mortality in assisted 65-74 years | 0.1500 | Uniform | (0.1000; 0.2000) | [39-42,46,50,52,53] |
| Mortality in assisted 75+ years | 0.3000 | Uniform | (0.2500; 0.3500) | [39-42,46,50,52,53] |
| Mortality in not assisted 65-74 years | 0.3000 | Uniform | (0.2000; 0.4000) | [39-42,46,50,52,53] |
| Mortality in not assisted 75+ years | 0.6000 | Uniform | (0.5500; 0.6500) | [39-42,46,50,52,53] |

| a) Risk of event in reference population (middle risk) × hazard ratio in usual care group. |
| b) Risk of event in reference population (high risk) × hazard ratio in usual care group. |
| c) Risk of event reference population (middle risk) × hazard ratio in programme group. |
| d) Risk of event in reference population (high risk) × hazard ratio in programme group. |

Note: * A local reference population was used to calculate the risk reduction in both usual care and hypertension programme groups.

Table 4 Results for the base case

| Strategy | Mean Cost | Incremental cost | Mean Effect | Incremental effect | Average cost/effect | ICER |
|----------|-----------|------------------|-------------|-------------------|--------------------|------|
| Usual care (IC95%) | $5,633.2 (2130 - 21027) | $10.78 LYG (10.15 - 11.24) | $522.44 $/LYG (163.92 - 2066.52) | |
| Programme (IC95%) | $5,828.5 (9336 - 32499) | $195.3 (11467 - 11472) | $10.96 LYG (10.37 - 11.37) | $0.18 LYG (0.08 - 0.29) | $519.99 $/LYG (194.80 - 1936.86) | $1,124.49 $/LYG (75660 - 76230) |

References: Mean effect: mean effectiveness; Incremental effect: incremental effectiveness; Average cost/effect: average cost-effectiveness; ICER: incremental cost-effectiveness; IC95%: 95% confidence interval; $: 2010 International Dollars; LYG: life-years gained. Discount rate 5%.
Nevertheless, a minimum 10 year-time horizon is needed.
The probabilistic sensitivity analysis evaluated uncertainty from all variables related to costs and outcomes used in the model. For example, even though we had exact costs for drug consumption (based on individual patients’ drug purchase), we also included a variable for percentage of drug coverage by the payer. This variable tried to capture different economic burdens according to the percentage of coverage provided.

Regarding variables on transition probabilities for events and outcomes, we checked consistency of local and international data before fitting the model. We worked with different sources of systolic blood pressure levels [48,49] to try to detect possible differences in risks that could change outcomes in the model. Subtle differences among different data sources did not affect original cardiovascular risk probabilities.

Mortality data from cardiovascular events were taken from the same populations used to fit other probabilities in the model [39-42]. Given the lack of data regarding 1 year-mortality of untreated cardiovascular events, we decided to adjust these probabilities using national mortality tables (adjusted for age and cause of death) and observational studies [46,47,50] and to explore the range in the sensitivity analysis.

Our study’s results are not directly comparable to previously published works [21,23,24] because they did not evaluate hard outcomes and/or have a long-term perspective. On the other hand, the German study [22] used a model that could allow broad comparisons. In general it can be said that they had findings similar to ours. This helps to corroborate results from both studies.

Of note, basal hypertension control in the usual care group from the study used to fit the model was high -60.4%- and mean basal blood pressure was 135/75 mm Hg [14]. In other settings, where basal control of hypertension is lower or the mean basal blood pressure is higher, a greater difference in effectiveness would be expected. For example, compared to a general elderly population in Argentina, the incremental effectiveness of “Hypertension Programme” would have been 1,22 LYG [48].

Even though the incremental effectiveness was relatively low for each patient, the model evaluated the effect of both types of hypertension treatment in all hypertensive patients in our population. Considering the impact of the programme in the 30,000 hypertensive patients in our setting, a total of 5,400 life years could be gained.

The model did not consider specific adverse events related to hypertension treatment for two reasons: 1) In previous studies, it was found that first-line antihypertensive drugs do not have more side effects than placebo [51]; and 2) to avoid double counting, because eventual costs and consequences of adverse events in hypertension treatment would be captured by the methodology used.

This study had some limitations. First, the effectiveness study used to compare treatment strategies was not a randomized controlled trial. It was impossible to perform one in our setting because of organizational restrictions...
(i.e. that could not prevent contamination of interventions between study groups). Nevertheless, “Hypertension Programme” and “Usual Care” groups had similar basal hypertension control in the originally published study, as mentioned above [14]. It did not have major methodological flaws, and its results were consistent with other studies [15-18]. Second, the study’s perspective was not societal. Third, outcomes did not capture quality of life. Time-frame and budgetary restrictions prevented us from considering resource use from a societal perspective or from assessing utility measures during the original study. In addition, after the success of this demonstration study, all patients were treated according to the Hypertension Programme, precluding us from assessing any actual difference between groups. Given that the aim of the study was to inform decision makers from a third-party payer, the perspective adopted is all right. Nevertheless, a societal perspective might have given useful information and allowed analysis from other sectors. The lack of consideration of health state values (e.g. through QUALYs, etc.) is an important limitation. It is not possible to predict a possible influence of this fact. Effectiveness could have been lower (for example stroke survivors would have contributed with less than one QUALY per each year survived), but the bigger proportion of patients without cardiovascular events in the “Hypertension Programme” group could have summed more QUALYs overall. Thus, it would be interesting to address this important issue with a specific study designed “ad hoc” (to assess this effect). Fourth, only the effect of (different options of) hypertension treatment was evaluated. We chose this approach because our original experience only considered hypertension treatment. Nevertheless, a more integral approach, considering also treatment of other cardiovascular risk factors could have been adopted. This would have probably increased the effectiveness seen. Fifth, the study was based on urban populations from middle income and high income countries. Results should not be extrapolated to rural or low income populations. Finally, uncertainties inherent to the model were not explored. Because of the time-horizon chosen, it would have been impossible to avoid the use of a model, although different assumptions could have been made.

Notwithstanding, the study had several strengths. First, data on costs and effectiveness -intermediate outcomes- used to fit the model were local and at patient-level. Costs were evaluated in detail, and its real distribution was fitted in the model. Second, resources used were informed in appropriate physical units and valued in International Dollars to favour comparisons in other settings. Third, consistency of local and international data on events and mortality was checked before fitting the model. The slight differences observed did not modify model results. Fourth, a hard-outcome measure -mortality- was used. Fifth, the model was built to capture costs and outcomes of people with and without hospital attention during acute cardiovascular events as in a “real-life” scenario. Different assumptions can be made in different settings according to local access to health services and/or the rate of asymptomatic events. Finally, a probabilistic sensitivity analysis was performed with all variables included in the model. Results were robust under a wide range of assumptions.

Conclusions
This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. Its results showed that the “Hypertension Programme” was cost-effective against “Usual Care” for hypertension treatment and that its results were robust against wide assumptions.

Our study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.

Additional material

Additional file 1: Table S1 - Basal characteristics of patients in original effectiveness study. Table showing basal clinical characteristics of the intervention and control groups in the original effectiveness study [14].

Additional file 2: Graphic S1 - Cost-effectiveness acceptability curves for different discount rates. Additional file 2, graphic: S1: Cost-effectiveness acceptability curves for different discount rates: A) 0.0; B) 0.03; C) 0.07; D) 0.12. Each graph shows green circles for “Usual care” and blue diamonds for “Hypertension Programme”. Willingness to pay expressed per 1000 (K) international dollars per life-year gained.

Abbreviations
AVM: acute myocardial infarction; HF: heart failure; HMO: health maintenance organization; ICER: incremental cost-effectiveness ratio; Int$: International Dollars; Int$/LYG: International Dollars per life-year gained; LYG: life-years gained; PAD: peripheral artery disease; PCP: primary care physician; PSA: probabilistic sensitivity analysis; SNOMED-CT: Systematized Nomenclature of Medicine-Clinical Terms; TIA: transient ischaemic attack; UA: unstable angina.

Author details
1Medical Programmes, Hospital Italiano de Buenos Aires, (Perón 4253, 2°), Ciudad de Buenos Aires, (C1199ABC), Argentina. 2Epidemiology Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, (Perón 4253, 2°), Ciudad de Buenos Aires, (C1199ABC), Argentina. 3Hypertension Section, Internal Medicine Department, Hospital Italiano de Buenos Aires, (Perón 4190, 2°), Ciudad de Buenos Aires, (C1199ABF), Argentina. 4Financial Department, Hospital Italiano de Buenos Aires, (Perón 4253, 2°), Ciudad de Buenos Aires, (C1199ABC), Argentina. 5Pharmacology Department, School of Medicine, Universidad Austral, (Perón 1500), Derqui, (B1629AHJ), Provincia de Buenos Aires, Argentina. 6Fundación Capital, (Sinclair 3088), Ciudad de Buenos Aires, (C1425FRD), Argentina. 7Strategic Management, Hospital Italiano de Buenos Aires, (Perón 4190, PB), Ciudad de Buenos Aires, (C1199ABH), Argentina. 8Health Informatics Department, Hospital Italiano de Buenos Aires, (Perón 4272, 3°), Ciudad de Buenos Aires, (C1199ABD), Argentina.

Authors’ contributions
All authors read and approved the final manuscript.
GP, CG, CP, SF, FGBQ, JC and ES contributed to study conception and design, GP, ER, GW and CA participated in the collection and assembly of data, GP, ER, GW, CA, CG, CP and ES contributed to analysis and interpretation of data; all authors participated in drafting of the article.

Competing interests
The authors declare that they have no competing interests.

Received: 15 February 2010 Accepted: 5 April 2011
Published: 5 April 2011

References
1. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991, 265(24):3253-3264.
2. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekblom T, Wester PO: Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338(8778):1281-1285.
3. Amery A, Birkenhager W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985, 1(8442):1349-1354.
4. Staessen JA, Fagard R, Thijs L, et al: Cardiovascular prevention and blood pressure effects of different blood-pressure-lowering regimens on isolated systolic hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350(9080):757-764.
5. Coope J, Warrender TS: Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986, 293(6535):1145-1151.
6. Medical Research Council trial of treatment of hypertension in older adults: principal results: MRC Working Party. BMJ 1992, 304(6824):405-412.
7. Tumbul F: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362(9393):1527-1535.
8. Staessen JA, Wang JG, Thijs L: Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003, 21(6):1055-1076.
9. Staessen JA, Gaiosimo J, Wang JG, et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000, 355(9207):865-872.
10. Guyeiffier F, Bouteil F, Bossel JP, et al: Effect of antihypertensive drug treatment on cardiovascular outcomes in older women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997, 126(10):761-767.
11. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trials Collaboration. Lancet 2000, 356(9246):1555-1566.
12. Beckett NS, Peters R, Fletcher AE, et al: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358(18):1887-1898.
13. Narayan KM, Ali MK, Koplan JP: Global noncommunicable diseases–where worlds meet. N Engl J Med 365(13):1196-1198.
14. Figar S, Waisman G, De Quirós FG, et al: Narrowing the gap in hypertension: effectiveness of a complex antihypertensive program in the elderly. Dis Manag 2004, Fall 7(3):235-243.
15. Garcia-Pena C, Thorogood M, Armstrong B, Reyes-Frausto S, Munoz O: Pragmatic randomized trial of home visits by a nurse to elderly people with hypertension in Mexico. Int J Epidemiol 2001, 30(6):1485-1491.
16. Fahey T, Schroeder K, Ebrahim S: Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2006, 4:CD00182.
17. Roumie CL, Easty TA, Grevey R, et al: Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann Intern Med 2006, 145(3):165-175.
18. Agewil S, Wikström J, Samuelsson O, Persson B, Andersson OK, Fagerberg B: The efficacy of multiple risk factor intervention in treated hypertensive men during long-term follow up. Risk Factor Intervention Study Group. J Intern Med 1994, 236(6):651-659.
19. Clark AM, Hartling L, Vandermeer B, McAlister FA: Meta-analysis: secondary prevention programs for patients with coronary artery disease. Annals of internal medicine 2005, 143(9):659.
20. Faxon DP, Schwartz M, Pasternak RC, et al: Improving quality of care through disease management: principles and recommendations from the American Heart Association's Expert Panel on Disease Management. Stroke 2004, 35(6):1527.
21. García-Peña C, Thorogood M, Wonderling D, Reyes-Frausto S: Economic analysis of a pragmatic randomised trial of home visits by a nurse to elderly people with hypertension in Mexico. Salud Pública de México 2002, 44:14-20.
22. Gandjour A, Stock S: A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 2007, 83(2-3):257-267.
23. Reis DB, Constantine RT, Orenstein D, et al: A cost evaluation of the Georgia Stroke and Heart Attack Prevention Program. Prev Chronic Dis 2006, 3(1):A12.
24. Johannesson M, Agewali S, Hartford M, Hedner T, Fagerberg B: The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men. J Intern Med 1995, 237(19-26).
25. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117(6):743-753.
26. Instituto Provincial de Estadísticas y Censos de la Provincia de San Luis. [http://www.santafede.gov.ar/index.php/web/Estructura-de-Gobierno/Ministerios/Gobierno-y- Reforma-del-Estado/Secretaria-de-Tecnologias-para-la-Gestion/Direccion-Provincial-del-Instituto-Provincial-de-Estadistica-y-Censos-de-la-Provincia-de-Santa-Fe/Indices-y-Precios/INDICES-Y-PRECIOS], [cited August 10th 2010].
27. Dirección Provincial de Estadísticas y Censos de la Provincia de San Luis. [http://www.estadistica.sanluis.gov.ar/estadisticas_paginas/Paginas.aspx?Paginald=76], [cited August 10th 2010].
28. Dirección General de Estadística y Censos de la Provincia de La Pampa. [http://www.estadisticapampala.gov.ar/index.php?option=com_content&task=blogcategory&id=15&Itemid=22], [cited August 10th 2010].
29. Dirección de Estadística y Censos de la Provincia de Entre Ríos. [http://www.entreeros.gov.ar/doc/], [cited August 10th 2010].
30. Dirección Provincial de Planeamiento Estadística y Censos - Provincia de Jujuy. [http://www.dippec.jujuy.gov.ar/], [cited August 10th 2010].
31. Fundación Capital. [http://www.fundacioncapital.org.ar/], [cited August 10th 2010].
32. International Monetary Fund: World Economic and Financial Surveys. World Economic Outlook Database 2010, April 2010 Edition.
33. College of American Pathologists: SNOMED Clinical Terms Technical Reference Guide. 2005.
34. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in health and medicine. Oxford University Press New York; 1996.
35. Lopes H: The Social Discount Rate: Estimates for Nine Latin American Countries. World Bank Policy Research Working Paper Series, 2008.
36. Lewington S, Clarke R, Qizilbash N, Petro R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2003, 360(9349):1903-1913.
37. Kannell WB, Cupples LA, D’Agostino RB: Sudden death risk in overt coronary heart disease: the Framingham Study. Am Heart J 1987, 113(3):799-804.
38. Kannell WB, Abbott RD: Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1986, 311(18):1144-1147.
39. Blanco P, Gagliardi J, Higa C, Diri A, Guetta J, Di D: Infarto agudo de miocardio. Resultados de la Encuesta SAC 2005 en la República Argentina. Rev Argent Cardiol 2007, 75:163-170.
40. Rosamond W, Flegal K, Furie K, et al: Heart Disease and Stroke Statistics–2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117(4):e25-e146.
41. Spotsa LA, Esnaola MM, Zamora R, Zuru MC, Fusinotti Q, Saposnik G: Quality of ischemic stroke care in emerging countries: the Argentinian National Stroke Registry (ReNACER). Stroke 2008, 39(11):3036-3041.
42. Grysewicz RA, Thomas K, Pandey DK: Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality, and risk factors. Neurologic clinics 2008, 26(4):871.

43. Augustovski FA, Irazola VE, Velazquez AP, Gibbons L, Craig BM: Argentine valuation of the EQ-5D health states. Value in Health 2009, 12(4):587-596.

44. National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal. 2004.

45. Weinstein MC, Toy EL, Sandberg EA, et al: Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 2001, 4(3):348-361.

46. Secretaría de Políticas Regulación e Institutos: Dirección de Estadísticas e Información de Salud. Ministerio de salud de la Nación. Argentina. Estadísticas Vitales - Información Básica Año 2006; 2007.

47. World Health Organization: United States of America. Mortality Table. 2005 [http://apps.who.int/whosis/database/mort/table1_process.cfm], [cited July 2009].

48. Pryzgoda P, Janson J, Oflaherty M, et al: Lack of effective blood pressure control among an elderly hypertensive population in Buenos Aires. Am J Hypertens 1998, 11(8 Pt 1):1024-1027.

49. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P: Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001, 37(3):869-874.

50. Rothwell PM, Coull AJ, Silver LE, et al: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005, 366(9499):1773-1783.

51. Materson BJ, Reda DJ, Cushman WC, et al: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993, 328(13):914-921.

52. Kleindorfer D, Panagos P, Pancholi A, et al: Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005, 36(4):720-723.

53. Perna E, Canella JPC, Marquez LL: Resultados finales del Registro HOSPICAL: evolución a corto y largo plazo de pacientes con insuficiencia cardíaca descompensada en Argentina. Rev Fed Arg Cardiol 2007, 36:152-161.

doi:10.1186/1478-7547-9-4

Cite this article as: Perman et al: Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model. Cost Effectiveness and Resource Allocation 2011 9:4.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit